Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Telix Pharmaceuticals (Innovations) Pty Ltd. has 4 pending office actions in Chemistry & Materials. The matters involve 3 distinct examiners and 4 distinct art units, showing that the pending work is distributed across several examination assignments rather than contained in one unit.
MCDERMOTT, JEANNIE is the busiest examiner, with 2 pending matters. That examiner therefore handles a larger share of the current activity than the other identified examiners. The spread across art units makes application-by-application review important, particularly when developing responses that must address different examination contexts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDERMOTT, JEANNIE | 2 | 60.4% | +15.1% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687806 | AGGREGATE SEPARATION METHOD | MCDERMOTT, JEANNIE | — |
| 18687283 | PREPARATORY PROCESS | MCDERMOTT, JEANNIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17622341 | ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR | NATARAJAN, MEERA | 1d overdue |
| 18687806 | AGGREGATE SEPARATION METHOD | MCDERMOTT, JEANNIE | — |
| 18687283 | PREPARATORY PROCESS | MCDERMOTT, JEANNIE | — |
| 18547286 | Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents | DONOHUE, SEAN R | — |
| Art Unit | Apps |
|---|---|
| 1777 | 1 |
| 1776 | 1 |
| 1618 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687806 | AGGREGATE SEPARATION METHOD | MCDERMOTT, JEANNIE | 1777 | §102§103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18687283 | PREPARATORY PROCESS | MCDERMOTT, JEANNIE | 1776 | §102§103§112 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18547286 | Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 17622341 | ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR | NATARAJAN, MEERA | 1643 | §103Other | Final Rejection | 1d overdue | Pending | Dec 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTelix Pharmaceuticals (Innovations) Pty Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 3 examiners.
Jeannie Mcdermott has the most, with 2 of Telix Pharmaceuticals (Innovations) Pty Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
